Abstract：
Multiple sclerosis (MS) is one of the most common idiopathic inflammatory demyelinating disease. One of the challenges in the treatment of MS is how to overcome relapses without severe adverse effects. Due to their immunoregulatory properties and safety, mesenchymal stem cells (MSCs), present a potential alternative for treatment for MS. The efficacy and safety of a long-term MSCs therapy in MS remain to be established. In this communication, we report the clinical condition and disease progression of an MS patient treated for 11 years, with multiple infusions of MSCs derived from either his bone marrow (BM), pooled human umbilical cords (UC), or from his own child umbilical cord. A male patient diagnosed as progressive MS (EDSS score 3) was enrolled into our study and received 1 × 106 cells/kg of MSCs, at least once a year for 9 years. The MSCs treatment was well tolerated with no significant side effects. Following the transplantation of MSCs, the overall EDSS scores of the patient decreased over the 10 years period of observation. MRI investigation did not reveal any new lesions. However, upon the cessation of the MSCs treatment, the EDSS score increased from 1.0 to 3.5, further supporting the notion that in such a patient, the transplantation of MSCs, had a significant beneficial effect. This case study is the first to report on the beneficial effects of multiple infusions of BM-MSC and umbilical cord mesenchymal stem cells (UC-MSCs) in a progressive MS patient, over a period of 11 years, in absence of any other treatments. Hence, multiple infusions of MSCs may provide a novel therapeutic avenue for patients with aggressive MS.
摘要：
多发性硬化（MS）是最常见的特发性炎症性脱髓鞘疾病之一。治疗MS的挑战之一是如何克服复发而没有严重的副作用。由于它们的免疫调节特性和安全性，间充质干细胞(MSCs),为MS的治疗提供了潜在的替代方案。MS中的长期MSC疗法的功效和安全性仍有待确定。在这份通讯中,我们报告的临床状况和疾病进展的MS患者治疗了11年，多次输注来自他的骨髓（BM）的MSCs，汇集的人脐带（UC），或者是他自己孩子的脐带.诊断为进行性MS（EDSS评分3）的男性患者被纳入我们的研究，并接受1×106细胞/kg的MSCs，至少一年一次，持续9年。MSC治疗具有良好的耐受性,没有显著的副作用。MSCs移植后,患者的总体EDSS评分在10年的观察期内下降.MRI检查未发现任何新的病变。然而,在MSC治疗停止后，EDSS评分从1.0增加到3.5，进一步支持这样的观点，即在这样的患者中，MSCs的移植，有显著的有益效果。本案例研究首次报道了BM-MSC和脐带间充质干细胞（UC-MSCs）在进行性MS患者中多次输注的有益作用，在11年的时间里，在没有任何其他治疗的情况下。因此，MSCs的多次输注可能为侵袭性MS患者提供新的治疗途径。
